Trials / Completed
CompletedNCT05207865
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
A Phase 4, Open-label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 441 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.
Detailed description
This is a post marketing required study being conducted to further evaluate the long-term safety and tolerability of a more frequent daily dosing regimen of rimegepant for the prevention of episodic migraine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rimegepant | rimegepant ODT 75mg daily |
Timeline
- Start date
- 2022-03-15
- Primary completion
- 2024-07-02
- Completion
- 2024-07-02
- First posted
- 2022-01-26
- Last updated
- 2025-09-03
- Results posted
- 2025-09-03
Locations
19 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05207865. Inclusion in this directory is not an endorsement.